Latest News & Features
Big Pharma
When it comes to life sciences, Boston is out on its own. LSIPR takes a look at innovation in the Olde Towne. 1 January 2012
Biotechnology
The patentability of biotech inventions should meet substantive requirements such as novelty, inventive step and industrial applicability, but EPO developments suggest that formalities are increasingly important. 1 January 2012
Biotechnology
The America Invents Act was signed into law in September 2011, and many biotech companies are still trying to make sense of the new legislation. Eldora Ellison and Eric Steffe consider one of the most important changes. 1 January 2012
Biotechnology
For the Biotechnology Industry Organization, key developing markets pose particular challenges in terms of
IP and also in a wider context. LSIPR spoke to Joe Damond and Lila Feisee about international affairs. 1 January 2012
Big Pharma
First instance courts in France have adopted controversial interpretations of an important Enlarged Board of Appeal decision, says Stéphane Agasse. 1 May 2011
Big Pharma
The European life sciences industry has a long history. Many of the major players trace their roots to before
the war, and often began as agricultural or chemical companies. LSIPR takes a look at the leading jurisdictions. 1 May 2011
Americas
BIO represents a broad constituency of biotechnology and life sciences companies. LSIPR talks to BIO president and CEO Jim Greenwood about patent reform, healthcare, court cases and plans for the future. 1 May 2011
Americas
With IP laws around the world subject to frequent and sometimes unpredictable changes, it can be difficult to keep abreast of everything you need to know. Richard Gough and Jane Woodhouse take a look. 1 May 2011
Asia
Israel patent practice is distinct from US and European practice in a number of respects. Moshe Tritel describes a number of such areas with important practical ramifications for applicants seeking to maximise their patent protection in Israel. 1 May 2011
Americas
As biotechnology patents continue to grow in importance, uncertainty remains on both sides of the Atlantic as to exactly what is patentable. Simon O’Brien and David Gass take a look. 1 May 2011